Catheter-directed Sclerotherapy Versus Surgical Resecction: Randomized Controlled Trial Comparing Ovarian Function and Therapeutic Efficacy After Treatment of Ovarian Endometrioma

Catheter-directed Sclerotherapy Versus Surgical Resecction: Randomized Controlled Trial Comparing Ovarian Function and Therapeutic Efficacy After Treatment of Ovarian Endometrioma

The primary purpose of this study is to compare residual ovarian function and therapeutic efficacy of surgical resection and catheter-directed sclerotherapy for ovarian endometrioma

Screening

• History, Physical examination
• Vital signs
• Laboratory test (Serum AMH, CA-125, HE-4) / EKG / MRI
• EHP-30

Intervention

• Surgical enucleation or catheter-directed sclerotherapy
• Laboratory test / EKG
• Adverse event monitoring

Follow-up visit #1 (1 month)

• Vital signs
• Lab test (AMH, CA-125) / Ultrasound
• Adverse event monitoring

Follow-up visit #2 (6 months)

• Vital signs
• Lab test (AMH, CA-125) / Ultrasound / Contrast-enhanced MRI
• EHP-30

Follow-up visit #3 (12months)

• Vital signs
• Lab test (AMH, CA-125) / Ultrasound
• EHP-30

Inclusion Criteria:

1. Women with symptomatic fibroids (age: 20 - 60 years old)

Exclusion Criteria:

1. Gynecologic malignancy
2. Ongoing infection or inflammation
3. Coagulopathy (platelet < 50,000 or INR > 1.5)
4. Extraovarian endometriosis
5. Serum AMH of 5 or higher
6. Drug allergy
7. Illiteracy
8. Pregnancy